The stamp of approval: IVF, vaccines and penicillin

In 1999, the Royal Mail's Patients' Tale Millennium issue placed four images side by side – a child being vaccinated, a patient on a hospital trolley (nursing care), the penicillin mould, and a sculptural 'test-tube baby'. It was a quiet public verdict about what belongs in the pantheon of global public good.

Vaccination and penicillin are the classic cases – British breakthroughs that changed the odds of survival and, in doing so, transformed population health and the economy, not just in the UK but globally. Smallpox was pushed out of human history; routine immunisation continues to avert deaths at scale. Antibiotics turned previously fatal infections – from battlefield wounds to puerperal sepsis – into treatable conditions. And the nursing stamp reminds us that no discovery travels alone: a workforce must comfort, monitor, and keep care safe if science is to reach the bedside.

IVF belongs in that conversation for a different reason. It does not reduce mortality; it creates possibility: parenthood for people whom biology would otherwise exclude. That outcome has demographic, social, and economic implications: how families are formed, how fertility choices interact with education and work, and how a society organises financing and equitable access.

Royal Mail's choice to place IVF alongside smallpox vaccination and penicillin, just two decades after the first IVF baby was born, was an argument that assisted reproduction would prove a public good on a grand scale. A further two decades later, the implications are coming into view.

The British provenance matters. Crucially, the UK did something else right: it wrote the rules. The Warnock Committee's recommendations led to the Human Fertilisation and Embryology Act (1990) and Human Fertilisation and Embryology Authority (HFEA), giving Britain a framework that protects patients, enables good science and sustains public trust. That stewardship is part of the reason IVF became mainstream medicine here, rather than a commercial free-for-all.

Scale is the test. The tally already runs to many millions of births, and the forward view is larger still. By 2100 (a century on from those stamps), the measurable global impact of IVF – those directly conceived via assisted reproduction, and the wider number of lives 'owed' to it – over generations, could be comparable in order of magnitude to the population-level effects by which we honour vaccination and penicillin. That claim is not about boasting, but rather is about the ledger we use for public-good medicine – not laboratory milestones, but reach.

If that is plausible, the next questions are practical and familiar.

First, fairness. Today, too many would-be parents face a postcode lottery for fertility care. If IVF is a public good, this is where we begin – a national effort to avoid that lottery with transparent criteria, sensible age and clinical thresholds and funding routes that are explainable and humane.

Second, capacity and quality. The direction of travel is clear: closed-system oocyte retrieval and vitrification; centralised, high-throughput embryology using robotics; artificial intelligence for decision support to reduce variation and improve predictability. These are the same industrial virtues – scale, quality control and learning curves – that once made vaccines and antibiotics universal. This is a space where public–private partnership makes sense, with independent providers expanding capacity and innovation under common standards, audit and outcomes reporting.

Third, trusted governance. The UK's Warnock/HFEA tradition has largely settled the core questions – consent, safety, research limits, and patient protection – while allowing innovation. As technologies evolve, the task is to maintain confidence: avoid overregulation that throttles supply and underregulation that erodes trust; keep ethics and transparency out in front.

Fourth, how we pay. IVF began as artisanal medicine; today it is mainstream, yet still costly and unevenly funded. Models that reward outcomes rather than activity, bundled pricing, insurance with success-linked reimbursement, or public funding calibrated to cost-effective pathways, would widen access without diluting standards.

The moral claim follows from the stamps. Vaccines save life. Penicillin preserves it. IVF creates it for those otherwise excluded. If vaccines and antibiotics changed the world because they reached the world, IVF will be judged the same way: by access, fairness and trust. Nursing – the fourth image – reminds us that none of this works without the professionals who deliver care, day after day, in clinics, theatres and recovery rooms.

This does not diminish the romance of the science; it completes it. The stamp set's quiet prophecy was that IVF would be counted in the same civic currency as vaccination and penicillin, by the breadth of its reach and the depth of its human consequence. That is exactly what Britain should aim to deliver, as it marks the centenary of Professor Sir Robert Edwards' birth – a public-good story with a global impact that avoids a UK postcode lottery, upholds the Warnock/HFEA standard of ethical stewardship, and uses a public–private partnership to scale capacity safely and fairly.

The stamps got it right. Vaccines save life; penicillin preserves it; IVF creates it. Let's make access fair and on time.